Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.

BJU International
Alexander KutikovStephen A Boorjian

Abstract

To present a multi-institutional experience evaluating the use of systemic therapy in patients undergoing cytoreductive nephrectomy (CN), as prospective randomized trials showed a survival benefit for CN in patients with metastatic renal cell carcinoma treated with immunotherapy, and these data have been extrapolated to support CN in the era of targeted therapy, but the likelihood that patients with metastatic kidney cancer who undergo CN will receive systemic treatment afterward remains poorly defined. In all, 141 patients who underwent CN between 1990 and 2008 were identified from our Institutional Kidney Cancer Registries. Kaplan-Meier analyses and Cox regression models were used to assess the effect of clinicopathological and perioperative variables on patients' subsequent receipt of systemic therapy, and survival after CN. Overall, 98 of the 141 patients (69.5%) received postoperative systemic treatment, at a median (range) of 2.5 (0.1-61.5) months after CN. In this group, 52 (53%) patients received immunotherapy, 34 (35%) targeted agents, and 12 (12%) other regimens. By contrast, 43 patients (31%) did not receive systemic therapy, because of rapid disease progression (13, 30%), decision for surveillance by medical oncolog...Continue Reading

References

Mar 1, 1977·The Journal of Urology·J E MontieD K Montague
Jul 1, 1995·The Journal of Urology·R T BennettJ Fleischmann
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P KavoliusM S Brady
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R J MotzerJ Ferrara
Oct 5, 2001·Lancet·G H MickischUNKNOWN European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S RetsasK MacRae
Feb 10, 2004·The Journal of Urology·Robert C FlaniganE David Crawford
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
May 12, 2007·European Urology·Paul C M S Verhagen
May 19, 2007·The Journal of Urology·Brian I Rini, Steven C Campbell
Jun 1, 2007·The New England Journal of Medicine·Gary HudesUNKNOWN Global ARCC Trial
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Aug 2, 2008·Current Opinion in Urology·Vitaly MargulisChristopher G Wood
Dec 23, 2008·The Journal of Urology·Primo N LaraUNKNOWN Southwest Oncology Group Trial S8949
Dec 23, 2008·The Journal of Urology·Anil A ThomasSteven C Campbell
Apr 18, 2009·The Journal of Urology·K Robin YabroffAlison Martin

❮ Previous
Next ❯

Citations

Jun 17, 2011·Der Urologe. Ausg. A·C Wiesner, A Haferkamp
Apr 7, 2010·World Journal of Urology·Paul Russo
Aug 4, 2010·Targeted Oncology·Eric A SingerRamaprasad Srinivasan
Nov 23, 2011·Current Urology Reports·Paul L Crispen, Michael L Blute
Apr 13, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T PowlesA Bex
Mar 20, 2014·PloS One·Yong WeiWen-Hui Qian
Jan 28, 2017·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Brandon J ManleySeth A Strope
Oct 2, 2015·Therapeutic Advances in Urology·Stephen H Culp
Jul 23, 2016·European Urology·Axel BexUNKNOWN European Association of Urology
Jun 29, 2011·Expert Review of Anticancer Therapy·Lance C PagliaroEric Jonasch
Jul 16, 2019·Current Opinion in Urology·Jeffrey GrahamDaniel Y C Heng
Feb 27, 2013·World Journal of Urology·Axel Bex, John Haanen
Nov 26, 2011·Expert Review of Anticancer Therapy·Srinivas VourgantiGennady Bratslavsky
Jun 22, 2012·Expert Review of Anticancer Therapy·Axel Bex, Tom Powles
Aug 16, 2014·BJU International·Anthony T CorcoranAlexander Kutikov
Oct 15, 2020·Nature Reviews. Urology·Kyle A BlumA Ari Hakimi
Oct 17, 2021·Current Urology Reports·Roser Vives DilmeJesús Moreno Sierra

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.